Methylation Sequencing Panel
Facilitate Epigenetics research with Celemics’ NGS solution
Overview
Methylation Sequencing
Methylation sequencing can identify the locations and levels of methylated DNA in a genome-wide or targeted manner for various applications of epigenetic research. Celemics’ solution for DNA methylation sequencing can provide more comprehensive and detailed patterns of either genome-wide or specific target region of your choice.
Standard Workflow of Targeted Methyl-seq
Standard Workflow of Targeted Methyl-seq
Standard Workflow of Targeted Methyl-seq
DNA
Sample
Methylated
adaptor
On-bead
conversion
protocol
Index PCR
Post-PCR
Library
Preparation
Bisulfite
Conversion
Target
Enrichment
Sequencing
Targeted
Methyl-seq Data
Celemics Proprietary Probe Design for Methyl-seq
Celemics Proprietary Probe Design for Methyl-seq
“G/A” panel
“C/T” panel
Pre-PCR
Bisulfite
conversion
Celemics Proprietary Probe Design for Methyl-seq
Features & Benefits
Probe Specifically Designed for Methyl-seq
Celemics introduces elaborate design considering the sequence alteration by bisulfite conversion. We perform comparison analysis of the sequences before and after bisulfite conversion, enabling accurate detection of methylation sites.
BI analysis for methylation sequencing
BI analysis for methylation sequencing
Alignment
FASTQ Filter
Methylation
Extractor
Visualization
Methylation
Pattern
Deduplication
Raw
Data
Bismark
Standard Analysis Pipeline Targeted Methyl-seq
Compatible with Various Sample Types and C/T Conversion Method
Along with proprietary probes and exclusive workflow for methyl-seq, this panel allows methylation analysis from various sample sources.
As method for bisulfite conversion preference can be diverse, we also offer a market leading quality of panel that is compatible with both enzyme or chemical C/T conversion method; no compromised sequencing data depending on the conversion method
High Reproducibilty of Methylation Pattern Analysis
The results demonstrate high reproducibility of the analysis, yielding the same methylation patterns when repeatedly tested with the identical specimens.
Related Products
Library Preparation Kit
Highly optimized, user- convenient NGS library preparation kit for all Celemics panels
CAS
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
CeleMag Clean-up Bead
Incomparable quality magnetic bead for simple, flexible, and reproducible purification
Customized NGS Panel
Customization to Next Level; tailored NGS panel customization and assay optimization
Highly optimized, user- convenient NGS library preparation kit for all Celemics panels
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
Incomparable quality magnetic bead for simple, flexible, and reproducible purification
Customization to Next Level; tailored NGS panel customization and assay optimization
Resources
Technical Resources
Safety Data Sheets
If you require the latest MSDS file, please contact us via ‘Contact Us‘.
MSDS_Methylation Sequencing Panel_Illumina
MSDS_Methylation Sequencing Panel_Thermo Fisher
MSDS_Methylation Sequencing Panel_MGI
References
Cancer Research and Treatment
Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)
Koo DH, Jung M, Kim YH, Jeung HC, Zang DY, Bae WK, Kim H, Kim HS, Lee CK, Kwon WS, Chung HC. Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: a Multicenter Phase Ib/II Study (K-MASTER-13). Cancer Research and Treatment. 2024 Apr 29.
10.4143/crt.2023.1324
Summary | celemics publications
#Oncology
#ctDNA Sample
# AlphaLiquid® 100 Panel
Purpose
Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting epidermal growth factor receptor (EGFR), HER2, and HER4. We present a phase Ib/II study of a combination of varlitinib and weekly paclitaxel as a second-line treatment for patients with EGFR/HER2 co-expressing advanced gastric cancer (AGC).
Result
Genomic alteration landscape in circulating tumor DNA analysis according to the progression-free survival (PFS), overall survival (OS), and EGFR/HER2 immunohistochemical expression (n=15).
Conclusion
A combination of varlitinib and paclitaxel displayed manageable toxicity and modest antitumor activity in patients with EGFR/HER2 co-expressing AGC who progressed after first-line chemotherapy.
Method
The circulating tumor DNA (ctDNA) was extracted from the patient’s plasma (10 mL) at two time points (before treatment and at the first response evaluation or end of the treatment). The DNA NGS library and solution-based target enrichment were performed at IMBdx, Inc. (Seoul, Korea), using AlphaLiquid100. The captured DNA libraries were sequenced using the Illumina NovaSeq 6000 platform (Illumina, San Diego, CA) in the 2×150 bp paired-end mode.
Related Product
Circulating Tumor DNA Panel for
Colorectal / Lung / Breast Cancer
The circulating tumor DNA (ctDNA) was extracted from the patient’s plasma (10 mL) at two time points (before treatment and at the first response evaluation or end of the treatment). The DNA NGS library and solution-based target enrichment were performed at IMBdx, Inc. (Seoul, Korea), using AlphaLiquid100. The captured DNA libraries were sequenced using the Illumina NovaSeq 6000 platform (Illumina, San Diego, CA) in the 2×150 bp paired-end mode.
| Colorectal Cancer | ||
|---|---|---|
| Sensitivity | Freq. 0.5% | 100% |
| Freq. 1.0% | 100% | |
| Specificity | 97.9% | |
| Breast Cancer | ||
|---|---|---|
| Sensitivity | Freq. 0.5% | 94.4% |
| Freq. 1.0% | 100% | |
| Specificity | 96.3% | |
| Lung Cancer | ||
|---|---|---|
| Sensitivity | Freq. 0.5% | 100% |
| Freq. 1.0% | 100% | |
| Specificity | 100% | |
Cancers
Discovery and Validation of Survival-Specific Genes in Papillary Renal Cell Carcinoma Using a Customized Next-Generation Sequencing Gene Panel
Hwang J, Bang S, Choi MH, Hong SH, Kim SW, Lee HE, Yang JH, Park US, Choi YJ. Discovery and Validation of Survival-Specific Genes in Papillary Renal Cell Carcinoma Using a Customized Next-Generation Sequencing Gene Panel. Cancers. 2024 Jan;16(11):2006.
10.3390/cancers16112006
Frontiers in Neurology
Case report: Compound heterozygous variants detected by next-generation sequencing in a Tunisian child with ataxia-telangiectasia
Ammous-Boukhris N, Abdelmaksoud-Dammak R, Ben Ayed-Guerfali D, Guidara S, Jallouli O, Kamoun H, Charfi Triki C, Mokdad-Gargouri R. Case report: Compound heterozygous variants detected by next-generation sequencing in a Tunisian child with ataxia-telangiectasia. Frontiers in Neurology. 2024 May 31;15:1344018.
10.3389/fneur.2024.1344018
Scientific Reports
Sex-specific survival gene mutations are discovered as clinical predictors of clear cell renal cell carcinoma
Hwang J, Lee HE, Han JS, Choi MH, Hong SH, Kim SW, Yang JH, Park U, Jung ES, Choi YJ. Sex-specific survival gene mutations are discovered as clinical predictors of clear cell renal cell carcinoma. Scientific Reports. 2024 Jul 9;14(1):15800.
10.1038/s41598-024-66525-9